Literature Review: Glucocorticoid-Induced Osteoporosis (GIOP) Therapy Based on Current Evidence

Article Sidebar

PDF
Published: Jun 24, 2026
DOI: https://doi.org/10.55885/jchp.v6i2.1023
Keywords:
Glucocorticoid-Induced Osteoporosis, Molecular Mechanisms, Bisphosphonates, Denosumab, Anabolic Therapy, Clinical Management

Main Article Content

Atika Ananda Putri
Medical Professional Study Program Student, Faculty of Medicine, Muslim University of Indonesia
Ida Royani
Department of Nutrition, Faculty of Medicine, Muslim University of Indonesia
Prema Hapsari Hidayati
Department of Internal Medicine, Faculty of Medicine, Muslim University of Indonesia

Abstract

Glucocorticoid-Induced Osteoporosis (GIOP) is the most common form of secondary osteoporosis resulting from long-term glucocorticoid use and is associated with an increased risk of fracture. The management of GIOP continues to evolve as new evidence emerges regarding pharmacological therapy, sequential strategies, and fracture risk-based approaches. This article aims to review glucocorticoid-induced osteoporosis (GIOP) therapy based on the current evidence. This study is a literature review with a search of articles from the PubMed database between 2023 and 2026. The literature used includes original research, systematic reviews, meta-analyses, and clinical guidelines relevant to glucocorticoid-induced osteoporosis (GIOP). Current evidence suggests that glucocorticoid-induced osteoporosis (GIOP) therapy includes bisphosphonates as first-line therapy, denosumab as an alternative in certain at-risk patients, and teriparatide in high-risk patients. Sequential therapy approaches (anabolic-to-antiresorptive) and treat-to-target strategies have been shown to be more effective in increasing and maintaining bone mass. Current evidence-based therapy for glucocorticoid-induced osteoporosis (GIOP) emphasizes an individualized, risk-based approach with a combination of pharmacological therapy, calcium and vitamin D supplementation, lifestyle modification, and regular monitoring. This comprehensive approach is essential to reduce fracture risk and improve quality of life in patients taking long-term glucocorticoids.

Article Details

How to Cite
Putri, A. A., Royani, I. ., & Hidayati, P. H. . (2026). Literature Review: Glucocorticoid-Induced Osteoporosis (GIOP) Therapy Based on Current Evidence . Journal of Community Health Provision, 6(2), 432-448. https://doi.org/10.55885/jchp.v6i2.1023
Issue
Vol. 6 No. 2 (2026): Journal of Community Health Provision
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

References

Agrawal, A. K., Rath, P. D., Chouhan, S., Bisaralli, R., Kalyani, H., & Bhagawati, J. (2025). Assessment of Glucocorticoid-Induced Osteoporosis Treatment by Prevailing Guidelines in a Tertiary Care Hospital. European Journal of Rheumatology, 12(3), e24046. https://doi.org/10.5152/eurjrheum.2025.24046

Ahmed, A. E., Alzaylaee, W. A., Suhluli, A. S., Essa, S. A., Bahkali, L. M., Hakami, A. M., ... & Almihbash, A. K. (2025). Denosumab Versus Bisphosphonates in Glucocorticoid-Induced Osteoporosis: A Systematic Review. Cureus, 17(12).

Anastasilaki, E., Paccou, J., Gkastaris, K., & Anastasilakis, A. D. (2023). Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management. Hormones, 22(4), 611-622. https://doi.org/10.1007/s42000-023-00491-1

Chen, C. L., & Wang, J. Y. (2024). Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment. Frontiers in Endocrinology, 15, 1407692. https://doi.org/10.3389/fendo.2024.1407692

Chen, J. F., Yu, S. F., Chiu, W. C., Ko, C. H., Hsu, C. Y., Lai, H. M., ... & Cheng, T. T. (2024). Development and comparison of treatment decision tools for Glucocorticoid-Induced osteoporosis. Diagnostics, 14(4), 452. https://doi.org/10.3390/diagnostics14040452

Cheng, C. H., Chen, L. R., & Chen, K. H. (2022). Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. International journal of molecular sciences, 23(3), 1376. https://doi.org/10.3390/ijms23031376

Cho, S. K., & Sung, Y. K. (2021). Update on glucocorticoid induced osteoporosis. Endocrinology and Metabolism, 36(3), 536-543. https://doi.org/10.3803/EnM.2021.1021

Dong, L., Jiang, L., Xu, Z., & Zhang, X. (2024). Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis. Frontiers in Pharmacology, 15, 1336075. https://doi.org/10.3389/fphar.2024.1336075

Florez, H., Carrasco, J. L., Barberá, M., Hernández-Rodríguez, J., Muxi, A., Mocritcaia, A., ... & Peris, P. (2025). Risk factors for glucocorticoid induced osteoporosis in young adults. Frontiers in endocrinology, 16, 1528962. https://doi.org/10.3389/fendo.2025.1528962

Gregson, C. L., Armstrong, D. J., Avgerinou, C., Bowden, J., Cooper, C., Douglas, L., ... & National Osteoporosis Guideline Group (NOGG). (2025). The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 20(1), 119. https://doi.org/10.1007/s11657-025-01588-3

Hofbauer, L. C., Compston, J. E., Saag, K. G., Rauner, M., & Tsourdi, E. (2025). Glucocorticoid-induced osteoporosis: novel concepts and clinical implications. The Lancet Diabetes & Endocrinology, 13(11), 964-979.

Humphrey, M. B., Russell, L., Danila, M. I., Fink, H. A., Guyatt, G., Cannon, M., ... & Uhl, S. (2023). 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis & Rheumatology, 75(12), 2088-2102. https://doi.org/10.1002/art.42646

Ishihara, N., Yamashita, S., Seiki, S., Tsutsui, K., Kato-Hayashi, H., Sakurai, S., ... & Hayashi, H. (2024). Evaluation of steroid-induced osteoporosis prevention using tracing reports in collaboration between hospitals and community pharmacists. Pharmacy, 12(3), 80. https://doi.org/10.3390/pharmacy12030080

Kapszewicz, M., Michalska-Kasiczak, M., & Sewerynek, E. (2026). Glucocorticoid-Induced Osteoporosis: Pathogenesis, the Impact of Different Administration Routes on Bone Mineral Density, and Fracture Risk and Treatment Options—A Narrative Review. Journal of Clinical Medicine, 15(7), 2488. https://doi.org/10.3390/jcm15072488

Kast, S., Jakob, F., Kohl, M., von Stengel, S., Kerschan-Schindl, K., Lange, U., ... & Kemmler, W. (2023). Exercise effects on glucocorticoid-induced bone loss in adults: a systematic review and meta-analysis. Rheumatology Advances in Practice, 7(1), rkad019. https://doi.org/10.1093/rap/rkad019

Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021). Understanding and managing corticosteroid-induced osteoporosis. Open Access Rheumatology: Research and Reviews, 177-190. https://doi.org/10.2147/OARRR.S282606

Laurent, M. R., Goemaere, S., Verroken, C., Bergmann, P., Body, J. J., Bruyère, O., ... & Gielen, E. (2022). Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the Belgian bone club. Frontiers in endocrinology, 13, 908727. https://doi.org/10.3389/fendo.2022.908727

Liang, H., Zhao, J., & Tian, T. (2023). Pharmacological interventions for glucocorticoid-induced osteoporosis: an umbrella review. Hormone and Metabolic Research, 55(08), 511-519. https://doi.org/10.1055/a-2112-1596

Noetzlin, S., Breville, G., Seebach, J. D., & Gastaldi, G. (2022). Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach. Swiss medical weekly, 152(0102), w30088-w30088. https://doi.org/10.4414/SMW.2022.w30088

Paccou, J., Yavropoulou, M. P., Naciu, A. M., Chandran, M., Messina, O. D., Rolvien, T., ... & Lems, W. F. (2024). Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. European journal of endocrinology, 191(6), G1-G17. https://doi.org/10.1093/ejendo/lvae146

Puksun, K., Pongchaiyakul, C., Pakchotanon, R., Narongroeknawin, P., Leosuthamas, P., Arunthanachaikul, T., & Chaiamnuay, S. (2025). Comparison of different intervention thresholds for the treatment of glucocorticoid-induced osteoporosis: a cross-sectional study. BMC rheumatology, 9(1), 38. https://doi.org/10.1186/s41927-025-00488-w

Ronchetti, S., Ayroldi, E., Ricci, E., Gentili, M., Migliorati, G., & Riccardi, C. (2021). A glance at the use of glucocorticoids in rare inflammatory and autoimmune diseases: still an indispensable pharmacological tool?. Frontiers in Immunology, 11, 613435. https://doi.org/10.3389/fimmu.2020.613435

Shrestha, P., Popuri, S. B., Hoffer, C., Qureshi, A., Barzilay, J., Dapaah, E. A., & Carbone, L. D. (2026). Management of glucocorticoid-induced osteoporosis in rheumatic diseases. Best Practice & Research Clinical Rheumatology, 102151. https://doi.org/10.1016/j.berh.2026.102151

Song, X., Zhang, Y., Yang, H., Xiong, F., & Chen, F. (2025). Advances in the study and treatment of glucocorticoid osteoporosis: A review. Medicine, 104(22), e42668. https://doi.org/10.1097/MD.0000000000042668

Squadrito, F., Imbalzano, E., Rottura, M., Arcoraci, V., Pallio, G., Catalano, A., ... & Bitto, A. (2023). Effects of genistein aglycone in glucocorticoid induced osteoporosis: A randomized clinical trial in comparison with alendronate. Biomedicine & Pharmacotherapy, 163, 114821. https://doi.org/10.1016/j.biopha.2023.114821

Su, P., Li, M., Xiao, J., & Bai, L. (2025). Effectiveness of anabolic and anti-resorptive agents for preventing postmenopausal osteoporosis fractures: a systematic review and network meta-analysis. Journal of Orthopaedic Surgery and Research, 20(1), 645. https://doi.org/10.1186/s13018-025-06040-3

Tanaka, Y., Soen, S., Hirata, S., Okada, Y., Fujiwara, S., Tanaka, I., ... & Fukumoto, S. (2024). The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis. Journal of Bone and Mineral Metabolism, 42(2), 143-154. https://doi.org/10.1007/s00774-024-01502-w

Yamasaki, S. (2023). Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective. Annals of hematology, 102(7), 1645-1656. https://doi.org/10.1007/s00277-023-05266-7

Yuan, C., Liang, Y., Zhu, K., & Xie, W. (2023). Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Journal of Orthopaedic Surgery and Research, 18(1), 447. https://doi.org/10.1186/s13018-023-03920-4

Zhang, T., Zhao, Z., & Wang, T. (2023). Pulsed electromagnetic fields as a promising therapy for glucocorticoid-induced osteoporosis. Frontiers in Bioengineering and Biotechnology, 11, 1103515. https://doi.org/10.3389/fbioe.2023.1103515